物质信息
ID:347876
名称和标识
别名
CabaserDostinexFCE-213361-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)ureaCabergoline1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea
IUPAC传统名
cabergoline
IUPAC标准名
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
化合物性质
安全信息
GHS警示性声明
P261-P305+P351+P338
GHS警示词
Warning
MSDS下载
RTECS编号
KE6167600
保存温度
2-8°C
德国WGK号
3
GHS危险品标识
急性毒性（口服，皮肤接触，吸入），类别4
皮肤刺激，类别2
眼刺激，类别2
皮肤过敏，类别1
特定目标器官毒性 -一次接触，类别3
GHS危险声明
H302-H315-H319-H335
危险公开号
36/37/38
安全公开号
26-36/37
欧盟危险性物质标志
刺激性 (Xi)理化性质
溶解度
DMSO: ≥10 mg/mL
外观
powder
产品相关信息
纯度
≥98% (HPLC)
Empirical Formula (Hill Notation)
C26H37N5O2
描述信息
Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
分子图谱
暂无数据
点击上传数据
参考文献
暂无数据
点击上传数据